Filing Details
- Accession Number:
- 0001387131-18-006797
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-12-14 20:01:52
- Reporting Period:
- 2018-12-12
- Accepted Time:
- 2018-12-14 20:01:52
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
25743 | Therapeuticsmd Inc. | TXMD | Pharmaceutical Preparations (2834) | 870233535 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1532233 | Brian Bernick | 6800 Broken Sound Pkwy Nw, Third Floor Boca Raton FL 33487 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-12-12 | 91,400 | $0.10 | 6,648,771 | No | 4 | M | Indirect | By BF Investment Enterprises, Ltd. |
Common Stock | Disposition | 2018-12-12 | 91,400 | $4.18 | 6,557,371 | No | 4 | S | Indirect | By BF Investment Enterprises, Ltd. |
Common Stock | Acquisiton | 2018-12-13 | 91,910 | $0.10 | 6,649,281 | No | 4 | M | Indirect | By BF Investment Enterprises, Ltd. |
Common Stock | Disposition | 2018-12-13 | 91,910 | $4.12 | 6,557,371 | No | 4 | S | Indirect | By BF Investment Enterprises, Ltd. |
Common Stock | Disposition | 2018-12-07 | 190,000 | $0.00 | 52,000 | No | 5 | G | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Indirect | By BF Investment Enterprises, Ltd. |
No | 4 | S | Indirect | By BF Investment Enterprises, Ltd. |
No | 4 | M | Indirect | By BF Investment Enterprises, Ltd. |
No | 4 | S | Indirect | By BF Investment Enterprises, Ltd. |
No | 5 | G | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2018-12-12 | 91,400 | $0.00 | 91,400 | $0.10 |
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2018-12-13 | 91,910 | $0.00 | 91,910 | $0.10 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
91,910 | 2012-01-01 | 2019-01-01 | No | 4 | M | Indirect |
0 | 2012-01-01 | 2019-01-01 | No | 4 | M | Indirect |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 3,000 | Indirect | By BF Management, LLC |
Footnotes
- The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.075 to $4.32, inclusive. The Reporting Person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.04 to $4.25, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported securities are held by the GP. As disclosed in footnote 1 above, the Reporting Person, together with his spouse as tenants by the entirety, holds a 70.6% membership interest in the GP. The Reporting Person disclaims beneficial ownership of the reported securities held by the GP, except to the extent of his pecuniary interest therein.